NCT03492710View on ClinicalTrials.gov

Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2019

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Primary Immune Deficiency Disorder
Interventions
BIOLOGICAL

Immunoglobulin

Administer volume of IGIV-SN to maintain a trough level of of 5g/L or more

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY